{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:46:18Z","timestamp":1792525578005,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.parkreldis.2026.109018","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:19:22Z","timestamp":1791785962000},"page":"109018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling disease progression among moderate-stage Parkinson's disease patients: A targeted literature review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-2080","authenticated-orcid":false,"given":"Amy R.","family":"Mulick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Wicklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"G\u00f8tzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.parkreldis.2026.109018_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.parkreldis.2026.109018_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-095610","article-title":"Global burden of Parkinson's disease from 1990 to 2021: a population-based study","volume":"15","author":"Li","year":"2025","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","article-title":"Economic burden of Parkinson's disease: a multinational, real-world, cost-of-illness study","volume":"11","author":"Chaudhuri","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"5","key":"10.1016\/j.parkreldis.2026.109018_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2026.109018_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1452741","article-title":"Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis","volume":"15","author":"Pauwels","year":"2024","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2026.109018_bib6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mds.22875","article-title":"Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times","volume":"25","author":"Zhao","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2026.109018_bib7","series-title":"A Phase 2, Randomized, double-blind, Sham surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson's disease","year":"2024"},{"key":"10.1016\/j.parkreldis.2026.109018_bib8","series-title":"exPDite-2: a Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants with Parkinson's disease","year":"2025"},{"key":"10.1016\/j.parkreldis.2026.109018_bib9","series-title":"A Natural History Study of Treated Parkinson's disease Patients Experiencing Motor Complications","year":"2025"},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25454-1","article-title":"Predictive modelling of Parkinson's disease progression based on RNA-sequence with densely connected deep recurrent neural networks","volume":"12","author":"Ahmed","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.109018_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19020672","article-title":"Predictive model of quality of life in patients with Parkinson's disease","volume":"19","author":"Candel-Parra","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"4","key":"10.1016\/j.parkreldis.2026.109018_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson progression marker initiative (PPMI)","volume":"95","author":"Parkinson Progression Marker","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.parkreldis.2026.109018_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.703158","article-title":"Development and validation of a prognostic model for cognitive impairment in Parkinson's disease with REM sleep behavior disorder","volume":"13","author":"Chen","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.parkreldis.2026.109018_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ensci.2016.11.003","article-title":"Predictive model for falling in Parkinson disease patients","volume":"5","author":"Custodio","year":"2016","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.parkreldis.2026.109018_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.977985","article-title":"Multi-predictor modeling for predicting early Parkinson's disease and non-motor symptoms progression","volume":"14","author":"Dou","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41531-024-00832-w","article-title":"Personalized progression modelling and prediction in Parkinson's disease with a novel multi-modal graph approach","volume":"10","author":"Lian","year":"2024","journal-title":"npj Parkinson's Dis."},{"issue":"12","key":"10.1016\/j.parkreldis.2026.109018_bib25","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/mds.29213","article-title":"Joint modeling study identifies blood-based transcripts link to cognitive decline in Parkinson's disease","volume":"37","author":"Luo","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2026.109018_bib26","article-title":"Motor progression in early-stage Parkinson's disease: a clinical prediction model and the role of cerebrospinal fluid biomarkers","volume":"12","author":"Ma","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.parkreldis.2026.109018_bib27","article-title":"A progression analysis of motor features in Parkinson's disease based on the mapper algorithm","volume":"15","author":"Ma","year":"2023","journal-title":"Front. Aging Neurosci."},{"issue":"5","key":"10.1016\/j.parkreldis.2026.109018_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/mds.25404","article-title":"Three simple clinical tests to accurately predict falls in people with Parkinson's disease","volume":"28","author":"Paul","year":"2013","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2026.109018_bib29","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1007\/s00415-016-8287-9","article-title":"External validation of a 3-step falls prediction model in mild Parkinson's disease","volume":"263","author":"Lindholm","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2026.109018_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nicl.2017.08.021","article-title":"Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images","volume":"16","author":"Rahmim","year":"2017","journal-title":"Neuroimage, Clin."},{"issue":"12","key":"10.1016\/j.parkreldis.2026.109018_bib31","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/mds.28730","article-title":"Prognostic modeling of Parkinson's disease progression using early longitudinal patterns of change","volume":"36","author":"Ren","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2026.109018_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107175","article-title":"A prediction model for the walking and balance milestone in Parkinson's disease","volume":"129","author":"Shao","year":"2024","journal-title":"Park. Relat. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2026.109018_bib33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/WNL.0000000000002437","article-title":"Development and external validation of a prognostic model in newly diagnosed Parkinson disease","volume":"86","author":"Velseboer","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.parkreldis.2026.109018_bib34","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/mdc3.14215","article-title":"Validation of a 5-Year prognostic model for Parkinson's disease","volume":"11","author":"Ribeiro","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"7","key":"10.1016\/j.parkreldis.2026.109018_bib35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp-2021-328365","article-title":"Combining biomarkers for prognostic modelling of Parkinson's disease","volume":"93","author":"Vijiaratnam","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12874-017-0415-4","article-title":"Predicting the multi-domain progression of Parkinson's disease: a Bayesian multivariate generalized linear mixed-effect model","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/cts.12492","article-title":"Dopamine transporter neuroimaging as an enrichment biomarker in early Parkinson's disease clinical trials: a disease progression modeling analysis","volume":"11","author":"Conrado","year":"2018","journal-title":"Clin. Transl. Sci."},{"issue":"6","key":"10.1016\/j.parkreldis.2026.109018_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178982","article-title":"A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease","volume":"12","author":"Hayete","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.parkreldis.2026.109018_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200092","article-title":"Genome-wide analysis of motor progression in parkinson disease","volume":"9","author":"Martinez Carrasco","year":"2023","journal-title":"Neurol. Genet."},{"issue":"6","key":"10.1016\/j.parkreldis.2026.109018_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/bmm-2016-0370","article-title":"Parkinson's disease biomarkers: perspective from the NINDS Parkinson's disease biomarkers program","volume":"11","author":"Gwinn","year":"2017","journal-title":"Biomarkers Med."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.109018_bib40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cpt.2277","article-title":"A disease progression model to quantify the nonmotor symptoms of Parkinson's disease in participants with leucine-rich repeat kinase 2 mutation","volume":"110","author":"Ahamadi","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.parkreldis.2026.109018_bib41","article-title":"Motor dysfunction in Parkinson's patients: depression differences in a latent growth model","volume":"16","author":"Wang","year":"2024","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1037\/a0025119","article-title":"Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling","volume":"26","author":"Zahodne","year":"2012","journal-title":"Neuropsychology"},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00415-019-09538-z","article-title":"Apathy as a behavioural marker of cognitive impairment in Parkinson's disease: a longitudinal analysis","volume":"267","author":"Martin","year":"2020","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2026.109018_bib44","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/psp4.13112","article-title":"Data-driven disease progression model of Parkinson's disease and effect of sex and genetic variants","volume":"13","author":"Jin","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.109018_bib45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1037\/neu0000583","article-title":"Depressive symptoms precede cognitive impairment in de novo Parkinson's disease patients: analysis of the PPMI cohort","volume":"33","author":"Jones","year":"2019","journal-title":"Neuropsychology"},{"issue":"5","key":"10.1016\/j.parkreldis.2026.109018_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268379","article-title":"Path analysis of biomarkers for cognitive decline in early Parkinson's disease","volume":"17","author":"Gramotnev","year":"2022","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.parkreldis.2026.109018_bib47","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2026.109018_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1040293","article-title":"Subtyping of early-onset Parkinson's disease using cluster analysis: a large cohort study","volume":"14","author":"Zhou","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.parkreldis.2026.109018_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.729755","article-title":"Cognitive decline in Parkinson's disease: a subgroup of extreme decliners revealed by a data-driven analysis of longitudinal progression","volume":"12","author":"Andersson","year":"2021","journal-title":"Front. Psychol."},{"key":"10.1016\/j.parkreldis.2026.109018_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2023.137435","article-title":"Motor progression phenotypes in early-stage Parkinson's disease: a clinical prediction model and the role of glymphatic system imaging biomarkers","volume":"814","author":"He","year":"2023","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.parkreldis.2026.109018_bib51","first-page":"405","article-title":"Bayesian longitudinal modeling of early stage Parkinson's disease using DaTscan images","volume":"11492","author":"Zhou","year":"2019","journal-title":"Inf. Process Med. Imaging"},{"issue":"2","key":"10.1016\/j.parkreldis.2026.109018_bib52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1109\/TMI.2020.3031478","article-title":"Robust bayesian analysis of early-stage Parkinson's disease progression using DaTscan images","volume":"40","author":"Zhou","year":"2021","journal-title":"IEEE Trans. Med. Imag."},{"key":"10.1016\/j.parkreldis.2026.109018_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1240971","article-title":"Multifactorial assessment of Parkinson's disease course and outcomes using trajectory modeling in a multiethnic, multisite cohort - extension of the LONG-PD study","volume":"15","author":"Chase","year":"2023","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41531-024-00712-3","article-title":"Progression subtypes in Parkinson's disease identified by a data-driven multi cohort analysis","volume":"10","author":"Hahnel","year":"2024","journal-title":"npj Parkinson's Dis."},{"issue":"6","key":"10.1016\/j.parkreldis.2026.109018_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233296","article-title":"Identifying and predicting Parkinson's disease subtypes through trajectory clustering via bipartite networks","volume":"15","author":"Krishnagopal","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.parkreldis.2026.109018_bib56","doi-asserted-by":"crossref","first-page":"906","DOI":"10.21037\/qims-21-425","article-title":"Longitudinal clustering analysis and prediction of Parkinson's disease progression using radiomics and hybrid machine learning","volume":"12","author":"Salmanpour","year":"2022","journal-title":"Quant. Imag. Med. Surg."},{"issue":"3","key":"10.1016\/j.parkreldis.2026.109018_bib57","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1017\/S0033291715002196","article-title":"Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis","volume":"46","author":"Landau","year":"2016","journal-title":"Psychol. Med."},{"issue":"7","key":"10.1016\/j.parkreldis.2026.109018_bib58","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/jnnp.2010.213652","article-title":"Depression and anxiety related subtypes in Parkinson's disease","volume":"82","author":"Brown","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"15","key":"10.1016\/j.parkreldis.2026.109018_bib12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder Society-sponsored revision of the unified parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2026.109018_bib59","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1208\/s12248-017-0058-8","article-title":"Modeling a composite score in Parkinson's disease using item response theory","volume":"19","author":"Gottipati","year":"2017","journal-title":"AAPS J."},{"issue":"10","key":"10.1016\/j.parkreldis.2026.109018_bib60","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/psp4.12853","article-title":"Application of longitudinal item response theory models to modeling Parkinson's disease progression","volume":"11","author":"Zou","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"9","key":"10.1016\/j.parkreldis.2026.109018_bib61","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/mds.29154","article-title":"Dissecting the domains of Parkinson's disease: insights from longitudinal item response theory modeling","volume":"37","author":"Luo","year":"2022","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2026.109018_bib62","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1111\/bcp.14777","article-title":"Modelling item scores of unified Parkinson's disease rating scale part III for greater trial efficiency","volume":"87","author":"Sheng","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.parkreldis.2026.109018_bib63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1208\/s12248-011-9293-6","article-title":"Bayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development","volume":"13","author":"Lee","year":"2011","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.109018_bib64","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcph.683","article-title":"Dose-response analysis of the effect of carbidopa-levodopa extended-release capsules (IPX066) in levodopa-naive patients with parkinson disease","volume":"56","author":"Mao","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.parkreldis.2026.109018_bib65","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3233\/JPD-230446","article-title":"Modeling of Parkinson's disease progression and implications for detection of disease modification in treatment trials","volume":"14","author":"Ribba","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib13","article-title":"Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study","volume":"9","author":"Chandler","year":"2021","journal-title":"J. Mark Access Health Pol."},{"issue":"3","key":"10.1016\/j.parkreldis.2026.109018_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cpt.1634","article-title":"Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson's disease to inform clinical trial designs","volume":"107","author":"Ahamadi","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.parkreldis.2026.109018_bib15","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2589-7500(21)00101-1","article-title":"Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning","volume":"3","author":"Severson","year":"2021","journal-title":"Lancet Digit. Health"},{"issue":"2","key":"10.1016\/j.parkreldis.2026.109018_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001215","article-title":"Understanding the progression of Parkinson's disease: a review","volume":"7","author":"Kempster","year":"2025","journal-title":"BMJ Neurol. Open"},{"issue":"12","key":"10.1016\/j.parkreldis.2026.109018_bib17","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1474-4422(09)70291-1","article-title":"Progression of Parkinson's disease in the clinical phase: potential markers","volume":"8","author":"Maetzler","year":"2009","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.109018_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41531-022-00331-w","article-title":"Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson's disease","volume":"8","author":"Lohle","year":"2022","journal-title":"npj Parkinson's Dis."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202600845X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202600845X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:33:36Z","timestamp":1792524816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380202600845X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":65,"alternative-id":["S135380202600845X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.109018","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling disease progression among moderate-stage Parkinson's disease patients: A targeted literature review","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.109018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109018"}}